Prodrugs of G protein-coupled receptor GPR52 agonists have been reported in a recent Heptares Therapeutics Ltd. patent as potentially useful for the treatment of psychosis, among others.
Arena Pharmaceuticals Inc. and Boehringer Ingelheim Pharma GmbH & Co. KG have jointly patented 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivative G protein-coupled receptor GPR52 agonists.
Suzhou Zion Pharma Technology Co. Ltd. has reported GTPase KRAS (G12C mutant) inhibitors described as potentially useful for the treatment of brain cancer.
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors have been reported in a Shanghai Institute of Organic Chemistry patent as potentially useful for the treatment of cancer, atopic dermatitis, psoriasis, macular degeneration, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel and Alzheimer’s disease, among others.
Research at Nanjing Minova Pharmaceutical Co. Ltd. has led to the development of water-soluble allopregnanolone derivatives acting as prodrugs and reported to be useful for the treatment of Alzheimer’s disease, epilepsy, traumatic brain injury, post-traumatic stress, seasonal mood disorder, essential tremor, dysthymia and postpartum depression, among others.
Researchers at Tuojie Biotech (Shanghai) Co. Ltd. have developed substituted 1,4-dihydro-1,6-naphthyridine amides characterized as mineralocorticoid receptor (MR) antagonists and reported to be useful for the treatment of hypertension, aldosteronism and heart failure.
A recent F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent describes compounds reported to be useful for the treatment of Escherichia coli infection.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Tongji Hospital have disclosed sulfonylurea compounds acting as bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of heart failure.
Montelino Therapeutics LLC has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor variant 7 (AR-v7)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
RSS